News that the Chinese economy faces much uncertainty and that its lending rates are rising hurt U.S. stock markets on Monday. But Chinese stock markets and equities, of course, got hit as well.
The Shanghai Composite Index fell 5.3% with Hong Kong’s Hang Seng dropping 2.2%.
The move to curb credit in China could threaten Chinese companies, "especially those in the private sector with weak credit quality, because it heightens the risk that banks will scale back lending to those companies,” according to analysts at Moody's Investors Service.
U.S. investors holding China- and Asia-themed ETFs may want to pay attention to how the latest news in the region is affecting these products, given some of the discrepancies in their performance.
As for the major China-focused ETFs, the SPDR S&P China (GXC) was trading down nearly 2% on Monday, while the iShares MSCI China Index (MCHI) declined about 1.6%. Year to date, the SPDR ETF is off about 15%, and the MCHI is down 16%. For short-sellers, however, there’s good news.
Top Heal Care Companies To Buy For 2014: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Advisors' Opinion:- [By Keith Speights]
Amgen (NASDAQ: AMGN ) is another company that's probably keeping track of what's going on. The more successful Keryx is with Zerenex, the fewer possible sales for Amgen's Epogen. �
- [By Maxx Chatsko]
Shares of Amgen (NASDAQ: AMGN ) have returned over 65% in the past year; 109% if dividends are included. The S&P 500 has returned just over 13%. Those market beating returns aren't easy to find just anywhere, but investors may be wondering if Amgen stock has any more room to run. Let's take a look at catalysts and headwinds to see if we can come to a conclusion.
Top Heal Care Companies To Buy For 2014: Carbon Energy Ltd(CNX.AX)
Carbon Energy Limited focuses on producing clean energy and chemicals feedstock from Underground Coal Gasification (UCG) syngas. UCG is an alternative coal mining method that converts coal into gas underground using a series of boreholes operated remotely from the surface. The company also holds the right to explore and lease coal tenements in Wyoming, the United States, and Montana/North Dakota, the United States. In addition, it has a joint venture with Hema Endustri to develop UCG projects in the Amasra coal tenements located on the coast of the Black Sea in northern Turkey. The company was formerly known as Metex Resources Ltd and changed its name to Carbon Energy Limited in June 2008. Carbon Energy Limited is headquartered in Milton, Australia.
Hot Cheap Stocks To Watch Right Now: Ampal-American Israel Corporation(AMPL)
Ampal-American Israel Corp. acquires interests in businesses located in the State of Israel or that are Israel-related. It invests in companies in energy, real estate and project development, and leisure. The company provides its investee companies with ongoing support through its involvement in the investees? strategic decisions and introduction to the financial community, investment bankers, and other potential investors both in and outside of Israel. Ampal-American Israel Corp. was founded in 1942 and is based in Herzliya, Israel with an additional office in New York, New York.
Top Heal Care Companies To Buy For 2014: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Bryan Murphy]
If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.
- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
Top Heal Care Companies To Buy For 2014: RXi Pharmaceuticals Corp (RXII)
RXi Pharmaceuticals Corporation (RXi), incorporated on September 8, 2011, is a development-stage company. The Company is a biotechnology company focused on discovering, developing and commercializing therapies addressing medical needs using RNA interference (RNAi)-targeted technologies. As of July 12, 2012, RXi was focusing on its internal therapeutic development efforts in fibrosis. RXI-109 is its RNAi product candidate, which is a dermal anti-scarring therapy that targets connective tissue growth factor (CTGF). The Company�� therapeutic platform consists of two main components: RNAi Compounds (rxRNA) and Advanced Delivery Technologies. RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self-delivering RNA. On April 26, 2012, it completed the spin-off transaction from Galena Biopharma, Inc. (Galena).
In January 2011, the Company announced research results in collaboration with Generex Biotechnology Corporation, and RXi�� wholly owned subsidiary Antigen Express, Inc., in developing vaccine formulations for immunotherapy. In January 2011, it announced initial results as part of its collaboration with miRagen Therapeutics, Inc. in creating microRNA mimics, or artificial copies of microRNAs, using the Company�� sd-rxRNA technology. In February 2011, it announced the initiation of RXi�� development program for RXI-109.
Top Heal Care Companies To Buy For 2014: AtriCure Inc.(ATRC)
AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. Its primary product line includes isolator synergy bipolar radio-frequency ablation clamps for open-heart procedures and minimally invasive procedures; ablation and sensing unit, a compact power generator that delivers bipolar radio-frequency (RF) energy; AtriCure switch box, a compact switch box providing the technology needed for the dual pulsing electrodes, and the ability to connect and toggle between multiple RF devices; isolator multifunctional pen, a disposable RF device enabling surgeons to toggle back and forth between temporary pacing, sensing, and stimulation and ablation; and coolrail linear ablation device, a disposable linear RF ablation device, which allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. The company also offers cryoabla tion system, which consists of various reusable and disposable devices, including the Frigitronics CCS-200 product line for cardiac ablation; and Cryo1, a disposable cryoablation device, as well as AtriClip system, which is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart. In addition, it sells enabling technologies, including Lumitip dissector to separate tissues to provide access to key anatomical structures targeted for ablation; and MicroPace ORLab system, a stimulating, mapping, and recording system enabling physicians to confirm the ablation lines being created are forming electrical barriers or lines of block. The company sells its medical devices to hospitals and medical centers in the United States and internationally. AtriCure, Inc. is headquartered in West Chester, Ohio.
Advisors' Opinion:- [By John Udovich]
Small cap heart stocks Sunshine Heart Inc (NASDAQ: SSH), Abiomed, Inc (NASDAQ: ABMD) and AtriCure Inc (NASDAQ: ATRC) each find different ways go to the heart of the problem for cardiac�patients and have all been good performers for investors this year. After all and according to statistics collected by the CDC, heart disease is the leading cause of death for both men and women as about 600,000 people die of heart disease in the United States every year���accounting�for 1 in every 4 deaths. Moreover, roughly 715,000 Americans have a heart attack every year and�ff these, 525,000 are a first heart attack and 190,000 happen to people who have already had one. In other words, there is a big market for the following small cap heart stocks to address:
Top Heal Care Companies To Buy For 2014: Charter Financial Corp.(CHFN)
Charter Financial Corporation operates as the holding company for CharterBank that provides various banking services to individuals and businesses in Georgia and Alabama. Its deposit products include demand, NOW, and money market accounts; savings deposits; time deposits; checking accounts; and certificates of deposit. The company's loan products comprise commercial real estate loans; one- to four-family residential mortgage loans; construction and development loans; commercial business loans; and consumer loans, such as home equity loans, lines of credit, auto loans, and second mortgage loans. It operates through 16 branch offices located in West Point, LaGrange, Newnan, Carrollton, Bremen, Covington, and Peachtree City, Georgia; and Auburn, Opelika, and Valley, Alabama, as well as through a loan production office located in Norcross, Georgia. The company was founded in 1954 and is based in West Point, Georgia. Charter Financial Corporation operates as a subsidiary of Fir st Charter, MHC.
Advisors' Opinion:- [By Tim Melvin]
I get somewhat amused every day by the thousands of traders who spend all day trying to figure out what the hot stocks like Twitter (TWTR) and Facebook (FB) are going to do every day. Owning stocks like these two banks — or ones I have mentioned before, like ESSA Bancorp (ESSA) and Charter Financial (CHFN) — will be a far more profitable and relaxing endeavor over the next few years.
Top Heal Care Companies To Buy For 2014: Silver Bay Realty Trust Corp (SBY)
Silver Bay Realty Trust Corp., incorporated on June 29, 2012, is focused on the acquisition, renovation, leasing and management of single-family properties. The Company generates all of its revenue by leasing its portfolio of single-family properties.
As of September 30, 2012, the initial portfolio consisted of more than 2,540 single-family properties. As of September 30, 2012, Two Harbors owned a portfolio of approximately 1,660 single-family properties through its wholly owned subsidiary, Two Harbors Property Investment LLC. The Company is managed by PRCM Real Estate Advisers LLC.
Advisors' Opinion:- [By Matt Koppenheffer and David Hanson]
In this segment of The Motley Fool's financials-focused show, Where the Money Is, analysts Matt Koppenheffer and David Hanson discuss some of their favorite tweets of the day. Among the companies covered are Silver Bay (NYSE: SBY ) , American Homes 4 Rent (NYSE: AMH ) , and Wal-Mart (NYSE: WMT ) .
- [By Rich Duprey]
Two Harbors had also issued a special dividend last quarter�to distribute the company's shares of Silver Bay Realty Trust (NYSE: SBY ) .�It had received 17.8 million shares of Silver Bay stock in exchange for contributing its portfolio of over�2,200 single-family homes to Silver Bay, concurrent with the closing of Silver Bay's IPO in December of 2012.
No comments:
Post a Comment